| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up |
59 |
| MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials |
29 |
| The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial |
29 |
| Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression |
29 |
| Psychotropics and the Microbiome: a Chamber of Secrets... |
26 |
| Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function |
23 |
| The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research |
21 |
| Long-lasting subjective effects of LSD in normal subjects |
21 |
| Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution |
21 |
| Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition |
20 |
| Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders |
19 |
| Extinction of instrumental (operant) learning: interference, varieties of context, and mechanisms of contextual control |
19 |
| Rodent models of impaired fear extinction |
19 |
| Effect of cannabidiolic acid and Delta(9)-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain |
18 |
| Inflammation in cancer and depression: a starring role for the kynurenine pathway |
17 |
| Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting |
16 |
| Do daily fluctuations in inhibitory control predict alcohol consumption? An ecological momentary assessment study |
16 |
| Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects |
16 |
| Abuse liability of mitragynine assessed with a self-administration procedure in rats |
15 |
| Microdosing psychedelics: personality, mental health, and creativity differences in microdosers |
15 |
| Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects |
15 |
| The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial |
15 |
| Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study |
14 |
| Effects of Delta 9-THC and cannabidiol vapor inhalation in male and female rats |
14 |
| Common neurocircuitry mediating drug and fear relapse in preclinical models |
14 |
| Context-induced relapse after extinction versus punishment: similarities and differences |
14 |
| A potential role for the gut microbiome in substance use disorders |
14 |
| Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome |
14 |
| The hidden therapist: evidence for a central role of music in psychedelic therapy |
14 |
| Resveratrol ameliorates estrogen deficiency-induced depression- and anxiety-like behaviors and hippocampal inflammation in mice |
13 |
| Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity |
13 |
| Gut microbiome and brain functional connectivity in infants-a preliminary study focusing on the amygdala |
13 |
| The transition to cocaine addiction: the importance of pharmacokinetics for preclinical models |
13 |
| Synthetic cathinone adulteration of illegal drugs |
13 |
| Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice |
13 |
| Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD |
12 |
| Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23 |
12 |
| Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-kappa B pathways |
12 |
| Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression |
12 |
| Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences |
12 |
| Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys |
11 |
| Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers |
11 |
| Ameliorative effect of fisetin against lipopolysaccharide and restraint stress-induced behavioral deficits via modulation of NF-B and IDO-1 |
11 |
| Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters |
11 |
| Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits |
10 |
| Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects |
10 |
| Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression |
10 |
| The 5-HT1B receptor - a potential target for antidepressant treatment |
10 |
| Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications |
10 |
| The role of microbiota and inflammation in self-judgement and empathy: implications for understanding the brain-gut-microbiome axis in depression |
10 |
